Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XYLOCAINE vs ARESTOCAINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lidocaine binds to and inhibits voltage-gated sodium channels in the neuronal membrane, stabilizing the membrane and preventing the initiation and conduction of nerve impulses, thereby producing local anesthesia.
Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.
Local anesthesia for infiltration, nerve block, epidural, spinal, and topical use,Treatment of acute ventricular arrhythmias (e.g., during cardiac surgery or myocardial infarction),Off-label: treatment of status epilepticus, neuropathic pain, and tinnitus
Local or regional anesthesia for dental procedures,Infiltration anesthesia,Nerve block anesthesia
1-5 mg/kg (max 300 mg) local infiltration; epidural: 1-2% solution, 5-20 m L.
2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.
Terminal elimination half-life is approximately 1.5 to 2 hours in adults, prolonged to 2-3 hours in patients with hepatic impairment, and may exceed 5 hours in neonates or patients with heart failure.
Terminal elimination half-life is approximately 1.5–2 hours in adults with normal hepatic and renal function; prolonged in hepatic impairment or congestive heart failure.
Primarily hepatic via CYP1A2 and CYP3A4 to active metabolites (monoethylglycinexylidide and glycinexylidide).
Primarily metabolized by the liver via hydrolysis by esterases (though it is an amide, it may be partially hydrolyzed) and conjugation. The major metabolic pathways involve CYP1A2 and CYP3A4.
Hepatic metabolism (primarily by CYP1A2 and CYP3A4) to metabolites, mainly monoethylglycinexylidide (MEGX) and glycinexylidide (GX); less than 10% excreted unchanged in urine. Renal excretion of metabolites: MEGX (70-80%) and GX (10-20%). Biliary/fecal elimination is minimal.
Renal excretion of unchanged drug and metabolites; approximately 90% excreted in urine as parent compound and metabolites (60% as unchanged drug, 30% as metabolites), with less than 10% fecal elimination.
Approximately 65-70% bound to plasma proteins, primarily alpha-1-acid glycoprotein (AAG) and, to a lesser extent, albumin.
Approximately 70% bound primarily to alpha-1-acid glycoprotein (AAG) and to a lesser extent albumin.
Volume of distribution (Vd) is 0.8-1.3 L/kg. Higher Vd in neonates (up to 2.75 L/kg) indicates extensive tissue distribution.
Volume of distribution is 0.8–1.5 L/kg, reflecting extensive tissue distribution; higher in neonates and infants.
Intravenous: 100%; Intramuscular: 70-90%; Epidural: near 100%; Topical: variable and low due to systemic absorption, typically <10%; Oral: less than 30% due to extensive first-pass metabolism.
Topical: variable, approximately 30–50% absorbed through intact skin; Oral: negligible due to extensive first-pass metabolism (bioavailability <10%); Intravenous: 100%.
No adjustment required for GFR >30 m L/min; avoid in severe renal impairment (GFR <30 m L/min) due to risk of accumulation.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
Child-Pugh A/B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
1-2 mg/kg (max 4.5 mg/kg) local infiltration; adjust based on lean body weight.
1-3 mg/kg intramuscularly every 60-90 minutes, max 200 mg per dose; maximum cumulative dose 400 mg/12 hours.
Reduce dose by 40-50% due to decreased clearance and increased sensitivity to CNS/cardiac effects.
Initiate at lowest effective dose (2 mg/kg) due to increased sensitivity and potential for prolonged duration; monitor for adverse effects.
None.
There is no FDA black box warning for Arestocaine hydrochloride.
Risk of local anesthetic systemic toxicity (LAST) including CNS and cardiovascular effects, especially with inadvertent intravascular injection or high doses,Use with caution in patients with hepatic impairment, severe renal impairment, or hypovolemia,May cause methemoglobinemia, especially in infants,Monitor ECG when used intravenously for arrhythmias
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,Risk of methemoglobinemia in patients with glucose-6-phosphate dehydrogenase deficiency
Hypersensitivity to lidocaine or amide-type local anesthetics,Stokes-Adams syndrome or severe heart block (for IV antiarrhythmic use),Severe hypotension or cardiogenic shock,Do not use for spinal anesthesia if patient has bleeding disorders or infection at injection site
Hypersensitivity to amide-type local anesthetics,Severe hypotension,Myasthenia gravis (relative contraindication),Bradycardia
No clinically significant food interactions reported.
No specific food interactions; avoid hot foods until numbness resolves to prevent burns.
First trimester: No increased risk of major malformations observed in human studies. Second and third trimesters: Potential for fetal bradycardia and central nervous system depression with high maternal serum levels. Use only if clearly needed.
Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. In second and third trimesters, risk of placental transfer and fetal bradycardia; use only if clearly needed.
Excreted into breast milk in low amounts (M/P ratio approximately 1.0). Considered compatible with breastfeeding; monitor for signs of local anesthetic toxicity in infant.
No data on excretion in human milk. M/P ratio unknown. Caution advised; discontinue breastfeeding or drug based on importance of drug to mother.
No standard dose reduction required. Increased plasma volume and protein binding changes may reduce free drug concentration; however, toxicity may occur with standard doses due to altered clearance. Use lowest effective dose and consider patient weight.
Increased plasma volume and decreased plasma protein binding may require dose adjustments. However, no established guidelines; use lowest effective dose and shortest duration.
Use minimum effective dose to avoid systemic toxicity; maximum dose without epinephrine is 4.5 mg/kg (not to exceed 300 mg), with epinephrine (1:200,000) is 7 mg/kg (not to exceed 500 mg). Rapid absorption from highly vascular areas (e.g., intercostal blocks) increases toxicity risk. Always aspirate before injection to prevent intravascular administration. Mixing with epinephrine prolongs duration and reduces peak plasma levels. For pediatric patients, calculate dose based on weight and use reduced concentrations (0.5-1%). In patients with hepatic impairment, reduce dose due to decreased metabolism. Concurrent use with CYP1A2 inhibitors (e.g., fluvoxamine) may increase lidocaine levels.
ARESTOCAINE HYDROCHLORIDE (presumed anesthetic) is not a recognized drug; likely a misspelling of articaine or similar. If referring to articaine, clinical pearls: 1) Onset within 1-3 minutes, duration 1-3 hours; 2) Metabolized by plasma esterases, caution in pseudocholinesterase deficiency; 3) Maximum dose 7 mg/kg (adults) to avoid CNS/cardiac toxicity; 4) Contains sulfites, avoid in allergic patients.
Avoid driving or operating machinery until numbness and effects have completely worn off.,Do not eat or drink until sensation returns to prevent biting your tongue or cheek.,Report any signs of allergic reaction (rash, difficulty breathing, swelling) to your healthcare provider immediately.,If you experience dizziness, blurred vision, ringing in ears, or metallic taste, seek emergency care.,Inform your doctor about all medications you take, especially heart medications, anticoagulants, or other local anesthetics.,Numbness and lack of sensation are normal during the procedure; do not scratch or rub the numbed area.
Avoid chewing or biting lips/cheeks while numb to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) immediately.,Do not consume hot foods or beverages until sensation returns.,Inform dentist of all medications, especially MAOIs or anticoagulants.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XYLOCAINE vs ARESTOCAINE HYDROCHLORIDE, answered by our medical review team.
XYLOCAINE is a Local Anesthetic that works by Lidocaine binds to and inhibits voltage-gated sodium channels in the neuronal membrane, stabilizing the membrane and preventing the initiation and conduction of nerve impulses, thereby producing local anesthesia.. ARESTOCAINE HYDROCHLORIDE is a Local Anesthetic that works by Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XYLOCAINE and ARESTOCAINE HYDROCHLORIDE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XYLOCAINE is: 1-5 mg/kg (max 300 mg) local infiltration; epidural: 1-2% solution, 5-20 m L.. The standard adult dose of ARESTOCAINE HYDROCHLORIDE is: 2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XYLOCAINE and ARESTOCAINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XYLOCAINE is classified as Category C. First trimester: No increased risk of major malformations observed in human studies. Second and third trimesters: Potential for fetal bradycardia and central nervous system depress. ARESTOCAINE HYDROCHLORIDE is classified as Category C. Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.